Voloridge Investment Management
KPTI icon

Voloridge Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

Voloridge Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,944
Closed -$1.75M – 1514
2022
Q2 		$1.75M Sell
25,944
-19,178
-43% -$1.76M 0.01% 1052
2022
Q1 		$4.99M Buy
45,122
+31,963
+243% +$3.98M 0.03% 638
2021
Q4 		$1.27M Buy
+13,159
New +$1.31M 0.01% 1204
2020
Q1 		– Sell
-3,900
Closed -$1.12M – 1246
2019
Q4 		$1.12M Buy
+3,900
New +$846K 0.02% 620

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Voloridge Investment Management's KPTI Position: Q3 2022 in Review

Voloridge Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2022, closing a stake of 25,944 shares — an estimated $1.75M sold.

Voloridge Investment Management first reported a position in KPTI in Q4 2019 and held it in 4 quarters. The position peaked at $4.99M in Q1 2022. 147 funds tracked by Wall St. Rank hold KPTI as of Q3 2022.

  • Voloridge Investment Management reported no remaining Karyopharm Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Voloridge Investment Management sold 25,944 Karyopharm Therapeutics shares in Q3 2022, an estimated $1.75M.
  • Voloridge Investment Management first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 4 quarters.
  • Voloridge Investment Management's Karyopharm Therapeutics position peaked at $4.99M in Q1 2022.
  • 147 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2022.

Based on Voloridge Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.